Self-injurious behavior and dopaminergic neuron system in neonatal 6- hydroxydopamine-lesioned rat: 1. Dopaminergic neurons and receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 1016-1030

  Yokoyama, Chihiro ^a,c   Okamura, Hitoshi ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE RECEPTOR; EMONAPRIDE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOMUTILATION; AUTORADIOGRAPHY; BRAIN HOMOGENATE; BRAIN INJURY; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG RECEPTOR BINDING; IMMUNOCYTOCHEMISTRY; NEUROTRANSMISSION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RAT; RECEPTOR UPREGULATION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANIMALS, NEWBORN; AUTORADIOGRAPHY; BENZAMIDES; BRAIN; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; FEMALE; HYPOTHALAMUS; NERVE FIBERS; NEURONS; ORGAN SPECIFICITY; OXIDOPAMINE; PREGNANCY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; REFERENCE VALUES; SELF MUTILATION; SUBSTANTIA NIGRA; TRITIUM; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 0030899430     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. 125I-SCH 23382. Brain Res. 408: 281-285, 1987
2. ALEXANDER, G. E. AND CRUTCHER, M. D.: Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13: 266-271, 1990.
3. 1 receptor-containing striatal neurons, Brain Res. 410: 1-11, 1987.
4. ARNT, J.: Antistereotypic effects of dopamine D-2 and D-2 antagonists after intrastriatal injection in rats, Pharmacological and regional specificity, Naunym-Schmiedeberg Arch. Pharmacol. 330; 97-104, 1985.
5. BARUSH, P. F., ARTAND, F., GODEHEN, G., BARBEITO, L., GLOWINSKI, J. AND CHERAMY, A.: Substance P and neurokinin a regulate by different mechanisms dopamine release from dendrites and nerve terminals of the nigrostriatal dopaminergic neurons. Neuroscience 25: 889-898, 1988.
6. BAUMEISTER, A. A. AND FRYE, G.: Self-injurious behavior in rats produced by intranigral microinjection of GABA agonists. Pharmacol. Biochem. Behav. 21: 89-95, 1984.
7. BECKSTEAD, R. M., DOMESTICK, V. B. AND NAUTA, W. J. H.: Efferent connections of the substantia nigra and ventral tegmental area in the rat, Brain Res. 175: 191-217, 1979.
8. 2) receptors. Eur. J. Pharmacol. 129: 367-370, 1986.
9. BJÖRKLUND, A. AND LINIDVALL, O.: Dopamine-containing system in the CNS. In Handbook of Chemical Neuroanatomy, Vol. 2, Classical Transmitter in the CNS, Part I, ed. by Björklund, A. and Hökfelt, T., pp. 55-122, Elsevier, Amsterdam, 1984.
10. BLANCHARD, V., RAISMAN-BOZARI, R., VYAS, S., MICHEL, P., JAVOY-AGID, F., UHL, G. AND AGID, Y.: Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of the rat mesencephalon. Mol. Brain Res. 22: 29-40, 1994.
11. BREESE, G. R., BAUMEISTER, A., NAPIER, T. C., FRYE, G. D. AND MUELLER, R. A.: Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxydopamine in rats treated neonatally with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 235: 287-295,1985.
12. BREESE, G. R., BAUMEISTER, A. A., MCCOWN, T. J., EMERICK, S. G., FRYE, G. D., CROTTY, K. AND MUELLER, R. A.: Behavior differnces between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological system in clinical sundromes with reduced brain dopamine, J. Pharmacol. Exp. Ther. 235: 287-295, 1984.
13. BREESE, G. R., CRISWELL, H. E., DUNCAN, G. E. AND MUELLER, R. A.: A dopamine deficiency model of Lesch-Nyhan disease - The neonatal-6-OHDA-lesioned rat. Brain Res. Bull. 25: 477-484, 1990.
14. 2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 240: 167-176, 1987a.
15. BREESE, G. R., HULEBAK, K. L., NAPIER, T. C., BAUMEISTER, A., FRYE, G. AND MUELLER, R. A.: Enhanced muscimol-induced behavioral responses after 6-OHDA lesions: relevant to susceptibility for self-mutilation behavior in neonatal lesioned rats. Psychopharmacology 91: 356-362, 1987b.
16. BURNS, R. S., CHIEUH, C. C., MARKEY, S. P., EBERT, M. H., JACOHOWTTZ, D. M. AND KOPIN, I.: A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A. 80: 4546-4550, 1983.
17. 1 receptor distribution. Dev. Brain Res. 58: 111-122, 1991.
18. CAMERON, D. L. AND WILLIAMS, J. T.: Dopamine Dl receptors facilitate transmitter release. Nature 366: 344-347, 1993.
19. CERRUTTI, C., WALTHER, D. M., KUHAR, M. J. AND UHL, G. R.: Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Mol. Brain Res. 18: 181-186, 1993.
20. CHERAMY, A., LEVIEL, V. AND GLOWINSKI, J.: Dendritic release of dopamine in the substantia nigra. Nature 289: 537-542, 1981.
21. CHRISTIE, R., BAY, C., KAUFMAN, I. A., BAKAY, B., BORDEN, M. AND NYHAN, W. L.: Lesch-Nyhan disease: Clinical experience with nineteen patients, Dev. Med. Child Neurol. 24: 293-306, 1982.
22. DAHLSTÖM, A. AND FUXE, K.: Evidence of the existence of monoamine containing, neurons in the central nervous system. 1. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. 62(Suppl-232): 1-55, 1964.
23. DEMAREST, K. T. AND MOORE, K. E.: Lack of high affinity transport system for dopmaine in the median eminence and posterior pituitary. Brain Res. 171: 545-551, 1979.
24. DESCARRIES, L., SOGHOMONIAN, J. J., GARCIA, S., DOUCET, G. AND BRUNO, J. P.: Ultrastructural analysis of the serotonin hyperinnervation in adult rat neostriatum following neonatal dopamine denervation with 6-hydroxydopamine Brain Res. 569: 1-13, 1992.
25. 1 receptors in adult rat neostrieatum A.: after neonatal 6-hydroxydopamine denervation. Brain Res. 536: 287-296, 1990.
26. 1 dopamine receptors during postnatal development. J. Neurochem. 61: 1255-1262, 1993.
27. DUNCAN, G. E., CRISWELL, H. E., MCCOWN, T. J., PAUL, I. A., MUELLER, R. A. AND BREESE, G. R.: Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 243: 1027-1034, 1987.
28. FALLON, J. H. AND MOORE, R. Y.: Catecholamine innervation of the basal forebrain III, Olfactory bulb, anterior olfactory nuclei, olfactory tubercle and piriform cortex. J. Comp. Neurol. 180: 533-544, 1978a.
29. FALLON, J. H. AND MOORE, R. Y.: Catecholamine innervation of the basal forebrain IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol. 180: 545-580, 1978b.
30. GASPAR, P., HEIZMANN, C. W. AND KAAS, J. H.: Calbindin D-28K in the dopaminergic mesocortical projection of a monkey (Aotus trivirgatus). Brain Res. 603: 166-172, 1993.
31. 1 receptor development depends on endogenous dopamine. Dev. Brain Res. 56: 137-140, 1990.
32. GEORGE, S. R. AND VAN LOON, G. R.: Characterization of high affinity dopamine uptake into the dopamine neurons of the hypothalamus. Brain Res. 234: 339-355, 1982.
33. GOLDSTEIN, M., KUGA, S., KUSANO, N., MELLER, E., DANCIS, J. AND SCHWARCZ, R-: Dopamine agonist induced self-mutilative behavior in monkeys with unilateral ventral tegmental lesions of the brainstem: Possible pharmacological model for Lesch-Nyhan syndrome. Brain Res. 367: 114-120, 1986.
34. GRAYBIEL, A. M., OHTA, K. AND ROFFLER-TARLOV, S.: Patterns of cell and fiber vulnerability in the mesostriatal system of the mutant mouse weaver. I. Gradents and compartments. J. Nourosci. 10: 720-733, 1990.
35. GRAYBIEL, A. M. AND RAGSDALE, C. W. J.: Biochemical anatomy of the striatum. In Chemical Neuroanatomy, ed. by Emson, P. C., pp. 427-504, Raven Press, New York, 1983.
36. GREEN, A. H.: Self-mutilation in schizophrenic children. Arch. General Psychiat. 17:234-244, 1967.
37. 1 receptors to striatonigral neurons. Brain Res. 528: 317-322, 1990.
38. HATTORI, T., FIBIGER, H. C. AND MCGEER, P. L.: Demonstration of a pallidonigral projection innervating dopaminergic neurons. J. Comp. Neurol. 162: 487-504, 1975.
39. HEFFNER, T. G. AND SEIDEN, L. S.: Impaired acquisition of an operant response in young rats depleted of brain dopamine in neonatal life. Psychopharmacology 79: 115-119, 1983.
40. HICKS, P. E., SCHOEMAKER, H. AMD LANGER, S. Z.: 5-HT receptor antagonist properties of SCH 23390 in vascular smooth muscle ad brain. Eur. J. Pharmacol. 105: 339-342, 1984.
41. HÖKFELT, T., MARTENSSON, R., BJÖRKLUND, A. AND KLEINAU, S.: Distributional maps of tyrosine hydroxylase immunoreactive neurons in the rat brain. In Handbook of Chemical Neuroanatomy, Vol. 2, Classical Transmitters in the CNS, Part 1, ed. by Björklund, A. and Hökfelt, T., pp. 277-379, Elsevier, Amsterdam, 1984.
42. IKEDA, T., OKAMURA, H., YUKOYAMA, C., ICHITANI, Y., NAGATSU, I. AND IBATA, Y.: Heterogenous damage of intraventricular 6-hydroxydopamine treatment on nigrostriatal dopaminergic neurons in the adult rat. Acta Histochem. Cytochem. 25: 726, 1992.
43. JINNAH, H. A., WOJCIK, B. E., HUNT, M., NARANG, N., LEE, K. Y., GOLDSTEIN, M., WAMSLEY, J. K., LANGLAIS, P. J. AND FRIEDMANN, T.: Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. J. Neurosci. 14: 1164-1175, 1993.
44. JONSSON, G.: Chemical lesioning techniques: Monoamine neurotoxins. In Handbook of Chemical Neuroanatomy, Vol. 1, Methods in Chemical Neuroanatomy, ed. by Björklund, A. and Hökfelt, T., pp. 463-507, Elsevier, Amsterdam, 1983.
45. KELLY, P. H., SEVIOR, P. W. AND IVERSON, S. D.: Amphetamine and apomorphine responds in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94: 507-522, 1975.
46. KOSTRZEWA, R. M. AND SALEH, M. I.: Impaired ontogeny of striatal dopamine D-1 and D-2 binding sites after postnatal treatment of rats with SCH-23390 and spiroperidol. Dev. Brain Res. 45: 95-101, 1989.
47. LAVOIE, B. AND PARENT, A.: Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. NeuroReport 2: 601-604, 1991.
48. LESCH, M. AND NYHAN, W. L.: A familial disorder of uric acid metabolism and central nervous system function. Am. J. Med. 36: 561-570, 1964.
49. 1 dopamine receptors in the medial prefrontal cortex, striatum amd nucleus accumbens of normal and neonatal 6-hydroxydopamine treated rats: A quantitive autoradiographic analysis. Dev. Brain Res. 62: 109-114, 1991.
50. LLOYD, K. G., HORNYKIEWICZ, O., DAVIDSON, L., SHANNAK, K., FARLEY, I., GOLDSTEIN, M., SHIBUYA, M., KELLEY, W. N. AND FOX, I. H.: Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N. Engl. J. Med. 305: 1106-1111, 1981.
51. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
52. LUTHMAN, J., BILIOLI, B., TSUTSSUMI, T., VERHOFSTAD, A. AND JONSSON, G.: Sprouting of striatal serotonin nerve terminals following selective lesions of nigrostriatal dopamine neurons in neonatal rat. Brain Res. Bull. 19: 269-274, 1987.
53. LUTHMAN, J., LINDQVIST, E., YOUNG, D. AND COWBURN, R.: Neonatal dopamine lesion in the rat results in enhansed adenylate cyclase activity without alterning dopamine receptor binding or dopamine- and adenosine 3′5′-monophosphate-regulated phosphoprotein (DARPP-32) immunoreactivity. Exp. Brain Res. 83: 85-95, 1990.
54. MAISTO, C. R., BAUMEISTER, A. A. AND MAISTO, A. A.: An analysis of variables related to self-injurious behavior among institutionalised retarded persons. J. Ment. Def. Res. 22: 27-36, 1978.
55. 1 receptors on striatonigral terminals via a pertussis toxin-sensitive coupling pathway. J. Neurosci. 14: 4494-4506, 1994.
56. 8 in rat forebrain. Brain Res. Bull. 28: 683-695, 1992.
57. MOGENSON, G. L., SWANSON, L. W. AND WU, M.: Neural projection from the nucleus accumbens to globus pallidus, substantia innominata and preopticlateral hypothalamic area: An anatomical and electrophysiological investigation in the rat. J. Neurosci. 3: 189-202, 1983.
58. NAGATSU, I., KONDO, Y., INAGAKI, S., KARASAWA, N., KATO, T. AND NAGATSU, T.: Immunofluorescent studies on tyrosine hydroxylase: Application for its axonal transport. Acta Histochem. Cytochem. 10: 494-499, 1977.
59. NEWMAN, R. AND WINANS, S. S.: An experimental study of the ventral striarum of the golden hamster. I. Neuronal connection of the nucleus accumbens. J. Comp. Neurol. 191: 167-192, 1980a.
60. NEWMAN, R. AND WINANS, S. S.: An experimental study of the ventral striatum of the golden hamster. II. Neuronal connections of the olfactory tubercle. J. Comp. Neurol. 191: 1980b.
61. NORMAND, E., POPOVICI, T., ONTENIENTE, B., FELLMANN, D., PIAYIER-TONNEAU, D., AUFFRAY, C. AND BLOCK, B.: Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons. Brain Res. 439: 39-46, 1988.
62. OADES, R. D. AND HALLIDAY, G. M.: Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res. Rev. 12: 117-165, 1987.
63. OKAMURA, H., YOKOYAMA, C. AND IBATA, Y.: Neonatal 6-hydroxydopamine lesioned rat: Behavioral characteristics and damage of dopaminergic neurons. Abstr. Int. Cathechol. Symp. 7: 238, 1992.
64. OKAMURA, H., YOKOYAMA, C., KAWAKAMI, F. AND IBATA, Y.: Relationship between the destruction of dopaminergic neurons and self-mutilation behavior in the neonatally 6-hydroxydopamine treated rats. Neurosci. Res. 14(Suppl. 125): 1991.
65. OKAMURA, H., YOKOYAMA, C., KAWAKAMI, F. AND IBATA, Y.: Topographic analysis of brain dopaminergic neuron systems in rats showing self-mutilation behavior following neonatal 6-hydroxydopamine treatment. 2. receptor autoradiographic study of dopamine D1 and D2 receptors. Soc. Neurosci. Abst. 19: 1245, 1993.
66. ONO, H. AND H. FUKUDA: Effect of methamphetamine on rat spinal cord: Dopamine receptor-mediated depression of monosynaptic reflex. Neuropharmacology 23: 637-642, 1984.
67. PALKOVITS, M., ZABORSZKY, L., BROWNSTEIN, M. J., FEKETE, M. I. K., HERMAN, J. P. AMD KANYICSKA, B.: Distribution of norepinophrine and dopamine in cerebral cortical areas of the rat. Brain Res. Bull. 4: 593-601, 1979.
68. PAXINOS, G. AND WATSON, C.: The Rat Brain in Stereotaxic Coordinates, 2nd ed., Academic Press, Sydney, Australia, 1986.
69. PHILLIPSON, O. T.: The cytoarchitecture of the interfascicular nucleus and ventral tegmental area of Tsai in the rat. J. Comp. Neurol. 187: 85-98, 1979.
70. 3H-SCH 23390 binding sites in the rat substantia nigra: Evidence for a presynaptic localization and innervation by dopamine. Life Sci. 39: 321-328, 1986.
71. 3H|SCH 23390 binding sites increase after chronic blockade of D-1 dopamine receptors. Eur. J. Pharmacol. 118: 367-370, 1985.
72. 2 receptors in adult rat neostriatum after neonatal dopamine denervation: Quantitative data from ligand binding, in situ hybridization and iontophoresis. Neuroscience 57: 635-648, 1993.
73. 3H-GABA release from slices of rat substantia nigra in vitro. Nature 268: 652-654, 1977.
74. ROBERTSON, G. S. AND ROBERTSON, H. A.: Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms, J. Neurosci. 9: 3326-3331, 1989.
75. SALEH, M. I. AND KOSTRZEWA, R. M.: Impaired striatal dopamine receptor development: differential D-1 regulation in adults. Eur. J. Pharmacol. 154: 305, 1988.
76. SANDY, K. R.: Self-mutilation in Tourette's syndrome. J. Child Neurol. 3: 147-148, 1987.
77. 3H]SCH 23390 binding sites in pars reticulata and pars compacta of the substantia nigra in the rat. Neurosci. Lett. 72: 265-271, 1986.
78. SHIMADA, S., KITAYAMA, S., WALTHER, D. AND UHL, G.: Dopamine transporter mRNA: Dense expression in ventral midbrain neurons. Mol. Brain Res. 13: 359-362, 1992.
79. SIMSON, P. E., JOHNSON, K. B., JUREVICS, H. A., CRISWELL, H. E., NAPIER, T. C., DUNCAN, G. E., MUELLER, R. A. AND BREESE, G. R.: Augumented sensitivity of D1-dopamine receptors in lateral but not medial striatum following 6-hydroxydopamine-induced lesions in the neonatal rat. J. Pharmacol. Exp. Ther. 263: 1454-1463, 1992.
80. 1 dopamine receptor-mediated substance P depletion in the strionigral neurons of rats subjects to neonatal dopaminergic denervation: Implications for self-injurious behavior. Brain Res. 500: 119-130, 1989.
81. SIVAM, S. P., BREESE, G. R., KRAUSE, J. K., NAPIER, T. C., MUELLER, R. A. AND HONG, J. S.: Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression. J. Neurochem. 49: 1623-1633, 1987.
82. SIVAM, S. P. AND KRAUSE, J. E.: Compensatory activation of substance P biosynthesis by L-dihydroxyphenylalanine in striatonigral neurons of neonatal dopaminergic denervated rats. J. Pharmacol. Exp. Ther. 254:433-439, 1990.
83. SKAGERBERG, G., BJÖRKLUND, A., LINDVALL, O. AND SCHMIDT, R. H.: Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res. Bull. 9: 237-244, 1982.
84. SMITH, R. D., COOPER, B. R. AND BREESE, G. R.: Growth and behavioral change in developing rats treated intracisternally with 6-hydroxydopamine: Evidence for involvement of brain dopamine. J. Pharmacol. Exp. Ther. 185: 609-619, 1973.
85. SNYDER, A. M., ZIGMOND, M. J. AND LUND, R. D.: Sprouting of serotonergic sfferents into striatum after dopamine-depleting lesions in infant rats: A retrograde transport and immunocytochemical study. J. Comp. Neurol. 245: 274-281, 1986.
86. SWANSON, L. W.: The projections of the ventral tegmental area and adjacent regions: A combined fluorescent retrograde tracer and immunofluolescence study in the rat. Brain Res. Bull. 9: 321-353, 1982.
87. TOOYAMA, I., WALKER, D., YAMADA, T., HANAI, K., KIMURA, H., MCGEER, E. G. AND MCGEER, P. L.: High molecular weight basic fibroblast growth factor-like protein is localized to a subpopulation of mesencephalic dopaminergic neurons in the rat brain. Brain Res. 593: 274-280, 1992.
88. TRIARHOU, L. C., NORTON, J. AND GHETTI, B.: Mesencephalic dopamine cell deficit involves areas A8, A9 and A10 in weaver mutant mice. Exp. Brain Res. 70: 256-265, 1988.
89. TSAI, C.: The optic tract and centers of the oppossum, Didelphis virginiana. J. Comp. Neurol. 39: 173-216, 1925.
90. VOORN, P., ROEST, G. AND GROENEWEGEN, H. J.: Increase of enkephaline and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412: 391396, 1987.
91. WASZCZAK, B. L. AND WALTERS, J.: Endogenous dopamine can modulate inhibition of substantia nigra pars reticulata neurons elicited by GABA iontophoresis or striatal stimulation. J. Neurosci. 6: 120-126, 1986.
92. WINCHEL, R. M. AND STANLEY, M.: Self-injurious behavior: A review of the behavior and biology of self-mutilation. Am. J. Psychiatry 148: 306-317 1991.
93. YAGITA, K., OKAMURA, H., YOKOYAMA, C. AND IBATA, Y.: Dopaminergic projection to the rat prefrontal cortex analyzed by a new retrograde neuronal tracer and immunocytochemistry. Abst. Int. Cath. Symp. 7: 357, 1992.
94. YOKOYAMA, C., OKAMURA, H. AND IBATA, Y.: Self-mutilation behavior and brain dopamine in neonatal 6-hydroxydopamine treated rats; 2. An autoradiographic analysis of dopamine D2 receptor using [3H]YM09151-2. Neurosci. Res. 17(Suppl.99): 1992.
95. YOKOYAMA, C., OKAMURA, H. AND IBATA, Y.: Resistance of hypothalamic dopaminergic neurons to neonatal 6-hydroxydopamine toxicity. Brain Res. Bull. 30: 551-559, 1993a.
96. YOKOYAMA, C., OKAMURA, H., NAKAJIMA, T. AND IBATA, Y.: Topographic analysis of brain dopaminergic neuron systems in rats showing self-mutilation behavior following neonatal 6-hydroxydopamine treatment. 1. Immunocytochemical study of dopaminergic neurons. Soc. Neurosci. Abstr. 19: 1245, 1993b.
97. 2 receptor group, in the rat brain and spinal cord. J. Comp. Neurol. 344: 121-136, 1994.